Tuesday, September 17, 2013

Current, New and Novel Therapy for Castration-Resistant Prostate Cancer part 4


Ipilimumab is a human monoclonal antibody that blocks CTLA-4, which inhibits the interaction between the T-cell receptor CD28 and B7 costimulatory molecules on APCs that leads to activation of T cells.[51]An ongoing randomized multicenter Phase III study is comparing ipilimumab with placebo in asymptomatic or minimally symptomatic patients with metastatic, chemotherapy-naive CRPC (ClinicalTrials.gov identifier: NCT01057810).[101] A similarly designed Phase III trial is comparing ipilimumab with placebo in postdocetaxel setting after radiation. Results from both studies are still forthcoming, but this drug has previously showed good activity in terms of PSA decline, as well as radiological response (ClinicalTrials.gov identifier: NCT00861614).[101]



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review